• Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)
• Combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death
• Launched in India in the same year as its launch in the U.S., making India the third countryin the world to receive access to this New Biological Entity (NBE)
